BriaCell Therapeutics Corp. (CVE:BCT – Get Rating) shares traded down 3.8% during mid-day trading on Friday . The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares changed hands during trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Trading Down 3.8 %
The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68. The business’s fifty day simple moving average is C$10.60 and its 200 day simple moving average is C$10.60. The stock has a market cap of C$168.68 million and a price-to-earnings ratio of -28.19.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.